Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Total Liabilities (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Total Liabilities for 6 consecutive years, with $215.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 23.77% to $215.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $215.5 million, a 23.77% increase, with the full-year FY2025 number at $215.5 million, up 23.77% from a year prior.
  • Total Liabilities was $215.5 million for Q4 2025 at GeneDx Holdings, up from -$292.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $407.6 million in Q2 2021 to a low of -$292.3 million in Q3 2025.
  • A 5-year average of $179.2 million and a median of $189.9 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 1266.33% in 2021, then plummeted 225.44% in 2024.
  • GeneDx Holdings' Total Liabilities stood at $166.0 million in 2021, then skyrocketed by 42.92% to $237.2 million in 2022, then decreased by 19.6% to $190.7 million in 2023, then fell by 8.71% to $174.1 million in 2024, then grew by 23.77% to $215.5 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Total Liabilities are $215.5 million (Q4 2025), -$292.3 million (Q3 2025), and $186.7 million (Q2 2025).